Cardiovascular Toxicity from Chemotherapy and Anticancer Treatment

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Cardiovascular toxicity is a potential short- or long-term complication of chemotherapy and other anticancer therapies. Cytotoxics, such as anthracyclines, or other biological agents have been implicated in causing clinically significant cardiac dysfunction. Many targeted agents have been introduced in clinical practice and rare, but serious, complications have been described. Further follow-up is needed to determine the exact profile and outcomes of related cardiac side effects. Some of them are irreversible, leading to progressive cardiovascular disease; some others induce reversible dysfunction with no long-term cardiac damage for the patient. Assessment of the prevalence, type, and severity of cardiac toxicity caused by various cancer treatments is a breakthrough topic for patient management. More research is needed to assess and manage the cardiovascular safety of patients treated with anticancer agents, beginning with a dynamic partnership between oncologists and cardiologists and the development of a new generation of "cardio-oncologic" investigators. A thoughtful risk-management plan generated by an organized collaboration between oncologists, cardiologists, and regulatory agencies can support developmental programs essential for anticancer agents with cardiac safety concerns.

Original languageEnglish
Title of host publicationHeart and Toxins
PublisherElsevier Inc.
Pages341-361
Number of pages21
ISBN (Print)9780124165991, 9780124165953
DOIs
Publication statusPublished - Sep 8 2014

Fingerprint

Antineoplastic Agents
Drug Therapy
Anthracyclines
Risk Management
Biological Factors
Patient Safety
Cardiovascular Diseases
Research Personnel
Safety
Therapeutics
Research
Neoplasms
Cardiologists
Oncologists
Cardiotoxicity

Keywords

  • Antiangiogenic agents
  • Cardiac toxicity
  • Chemotherapy
  • Targeted drugs
  • Trastuzumab

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Cardiovascular Toxicity from Chemotherapy and Anticancer Treatment. / Esposito, Angela; Gelao, Lucia; Criscitiello, Carmen; Curigliano, Giuseppe.

Heart and Toxins. Elsevier Inc., 2014. p. 341-361.

Research output: Chapter in Book/Report/Conference proceedingChapter

@inbook{62346a2928d349fea819c2c8ced761b6,
title = "Cardiovascular Toxicity from Chemotherapy and Anticancer Treatment",
abstract = "Cardiovascular toxicity is a potential short- or long-term complication of chemotherapy and other anticancer therapies. Cytotoxics, such as anthracyclines, or other biological agents have been implicated in causing clinically significant cardiac dysfunction. Many targeted agents have been introduced in clinical practice and rare, but serious, complications have been described. Further follow-up is needed to determine the exact profile and outcomes of related cardiac side effects. Some of them are irreversible, leading to progressive cardiovascular disease; some others induce reversible dysfunction with no long-term cardiac damage for the patient. Assessment of the prevalence, type, and severity of cardiac toxicity caused by various cancer treatments is a breakthrough topic for patient management. More research is needed to assess and manage the cardiovascular safety of patients treated with anticancer agents, beginning with a dynamic partnership between oncologists and cardiologists and the development of a new generation of {"}cardio-oncologic{"} investigators. A thoughtful risk-management plan generated by an organized collaboration between oncologists, cardiologists, and regulatory agencies can support developmental programs essential for anticancer agents with cardiac safety concerns.",
keywords = "Antiangiogenic agents, Cardiac toxicity, Chemotherapy, Targeted drugs, Trastuzumab",
author = "Angela Esposito and Lucia Gelao and Carmen Criscitiello and Giuseppe Curigliano",
year = "2014",
month = "9",
day = "8",
doi = "10.1016/B978-0-12-416595-3.00011-6",
language = "English",
isbn = "9780124165991",
pages = "341--361",
booktitle = "Heart and Toxins",
publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - Cardiovascular Toxicity from Chemotherapy and Anticancer Treatment

AU - Esposito, Angela

AU - Gelao, Lucia

AU - Criscitiello, Carmen

AU - Curigliano, Giuseppe

PY - 2014/9/8

Y1 - 2014/9/8

N2 - Cardiovascular toxicity is a potential short- or long-term complication of chemotherapy and other anticancer therapies. Cytotoxics, such as anthracyclines, or other biological agents have been implicated in causing clinically significant cardiac dysfunction. Many targeted agents have been introduced in clinical practice and rare, but serious, complications have been described. Further follow-up is needed to determine the exact profile and outcomes of related cardiac side effects. Some of them are irreversible, leading to progressive cardiovascular disease; some others induce reversible dysfunction with no long-term cardiac damage for the patient. Assessment of the prevalence, type, and severity of cardiac toxicity caused by various cancer treatments is a breakthrough topic for patient management. More research is needed to assess and manage the cardiovascular safety of patients treated with anticancer agents, beginning with a dynamic partnership between oncologists and cardiologists and the development of a new generation of "cardio-oncologic" investigators. A thoughtful risk-management plan generated by an organized collaboration between oncologists, cardiologists, and regulatory agencies can support developmental programs essential for anticancer agents with cardiac safety concerns.

AB - Cardiovascular toxicity is a potential short- or long-term complication of chemotherapy and other anticancer therapies. Cytotoxics, such as anthracyclines, or other biological agents have been implicated in causing clinically significant cardiac dysfunction. Many targeted agents have been introduced in clinical practice and rare, but serious, complications have been described. Further follow-up is needed to determine the exact profile and outcomes of related cardiac side effects. Some of them are irreversible, leading to progressive cardiovascular disease; some others induce reversible dysfunction with no long-term cardiac damage for the patient. Assessment of the prevalence, type, and severity of cardiac toxicity caused by various cancer treatments is a breakthrough topic for patient management. More research is needed to assess and manage the cardiovascular safety of patients treated with anticancer agents, beginning with a dynamic partnership between oncologists and cardiologists and the development of a new generation of "cardio-oncologic" investigators. A thoughtful risk-management plan generated by an organized collaboration between oncologists, cardiologists, and regulatory agencies can support developmental programs essential for anticancer agents with cardiac safety concerns.

KW - Antiangiogenic agents

KW - Cardiac toxicity

KW - Chemotherapy

KW - Targeted drugs

KW - Trastuzumab

UR - http://www.scopus.com/inward/record.url?scp=84942626385&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942626385&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-416595-3.00011-6

DO - 10.1016/B978-0-12-416595-3.00011-6

M3 - Chapter

AN - SCOPUS:84942626385

SN - 9780124165991

SN - 9780124165953

SP - 341

EP - 361

BT - Heart and Toxins

PB - Elsevier Inc.

ER -